First studies conducted in AML patient cells harboring 2-HG-producing IDH1/2 mutations uncovered an altered cellular epigenetic landscape and a myeloid bias characteristic of AML patients with TET2 loss of function [52,90,134,143]. The gene discussed is IDH1; the disease is acute myeloid leukemia.